sgusers的部落格

三星電子IT和移動通信業務部總裁申宗均（JK Shin）在一次投資者會議上透露，迷你倉三星平板電腦業務增長迅速，今年銷量已經達到4000萬台的驚人數字，比2012年的兩倍還多。從手寫平板電腦GALAXY Note 10.1，到8英寸的GALAXY Note 8.0，三星已經在平板電腦市場攫取了超過20%的份額。而這一次被申宗鈞寄予厚望的，則是三星與GALAXY Note 3智能手機同步推出的GALAXY Note系列新一代平板電腦——GALAXY Note 10.1（2014版）。在同質化中創造差異在高度同質化的平板電腦市場里，三星設計開發了GALAXY Note 10.1（2014版）這款“特立獨行”的產品。機身後蓋採用仿皮質材料，具有柔和的紋理和溫潤的觸感，這種材質不僅讓整機手感提升，還能減少劃痕、防止裂紋。機身邊緣則採用了如同手工縫製的精緻針腳設計，增加了私人定制成衣般的高檔質感，再配上機身側面的立體拉絲設計，整體效果仿佛一本閉合的記事薄，恰到好處地詮釋了“Note”的創意靈感。而在硬件配置方面，GALAXY Note 10.1（2014版）也達到了行業內的高端水平，高達2560x1600的超高分辨率LCD大屏幕帶來豐富的視覺體驗，內部則採用了儲存倉核1.9GHz+四核1.3GHz處理器和3GB RAM內存。這樣的硬件配置已經達到了業界的領先水平。從消費內容到創造內容隨著三星創新性的推出配備有“智能筆”S Pen的手寫平板電腦之後，平板電腦正在逐漸擺脫單純的“消費內容”的角色，越來越多的具備了“創造內容”的作用。GALAXY Note 10.1（2014版）配備的“智能筆”S Pen擁有多項“神奇”的功能。“智能備忘錄”能夠將手寫筆跡鏈接到7項最常用功能；“隨剪隨貼”能夠將隨時發現和截取的素材分類收集和自動整理，形成用戶個性化剪貼庫；“截屏編寫”能夠對手機當前顯示的內容進行快速截屏，同時�用手寫功能，方便用戶隨時對截取的畫面進行批注。此外，“S搜索”能夠進行全局的內容搜索，不僅能搜索關鍵字，還能篩查時間、位置等特定形式的內容。打開“隨筆窗口”，則可通過S Pen在屏幕隨意位置繪製出一個供特定程序運行的小窗口，並令其浮于當前屏幕之上獨立運行，成為另一種形式的多任務處理。通過S Pen所實現的種種創新功能，大大增強了用戶處理日常任務的效率。憑借強大的整體研發實力和產業鏈垂直整合能力，三星平板電腦無論是新品推出速度還是產品創新力度均領先于主要競爭對手，而這，也正是三星手機能夠取得成功的兩大殺手�。迷你倉最平

因郵遞業務萎縮，迷你倉中華郵政活化資產、跨入旅館業當「包租公」，陸續已有不少支分局改建成平價旅館。除了台東郵局的三處支局正進行改建，明年下半年完工啟用，台北郵局東門分局更早在前年就已完成改建，月收九十萬元租金。台東郵局經理蔡居隆表示，中華郵政全台鄉鎮都有據點，為活化部分支局閒置空間，總公司試辦以會館概念，提供遊客平價旅館新選擇，台東已選定卑南、豐田及初鹿等三處支局。蔡居隆指出，初鹿支局位於花東縱谷，是第一波改建對象，規畫六到八間迷你倉樂器間；豐田支局閒置空間大，可容納小型旅行團；卑南支局鄰近台東市區，除了既有房舍翻修出租民宿，郵局擬在原卑南支局旁買地，擴大作旅館，預計明年動工，二○一七年啟用。對於郵局進軍旅宿業，台東娜路彎大酒店公關經理邱盛堂表示，可見台東觀光業火熱程度，業者樂觀其成。中華郵政除在後山拚觀光， 緊鄰台北市永康商圈、具八十年歷史的東門郵局，前年也與捷運聯合開發，改建為樓高十二層的現代大樓，三樓以上出租經營商務旅館，每月帶進約九十萬元的租金收入。迷你倉西貢

With so many barely distinguishable shades on the colour chart, choosing paint colours can be a pleasure and a painOkay, for the backyard, I want this colour, pointing excitedly to the little square of paint in the catalogue labelled Zambezi Rocks.迷你倉It's got a cool name, I reasoned. It sounds like some sort of slogan for an African freedom fighter.My interior designer K.C. made a face."Years ago, when you first bought the house, I asked you to choose a colour for the roof terrace and what did you choose?" he said drily.Um, Zambezi Rocks? I treaded cautiously, realising a scolding was around the corner."And then what happened?"It was all coming back to me now. The sick sinking feeling of a mistake that grew and grew every time I stepped out onto the terrace.Until one day when one of my close friends finally could not hold back his frank assessment."It's bird-s*** green, isn't it?"Within a month, I had the terrace repainted.Now I'm renovating my house again and am about to fall back into the same old mossy green-grey trap.Colour is such a funny thing. It's based on the rock-solid scientific foundations of physics and human physiology, yet it's so subjective.Two people can look at the same colour and disagree on whether it is blue or green, even before there is any conversation as to whether it's a "nice" colour.Great philosophers like Ludwig Wittgenstein have even argued that colour is such a slippery concept that what holds it together is nothing more than an artificial truce among people.In reality, they all individually see something slightly different, but agree to call the colour "purple" or "orange".As a result, colour isn't a logically uniform or absolute concept and words and meaning can go only so far.He once famously said: "There is gold paint, but Rembrandt didn't use it to paint a golden helmet."Then, there is the whole other science of what emotions or states of mind that colours can stir up.Apparently in psychology, there are four primary colours. Red has the longest wavelength and is easily seen, so it is the "physical" colour that denotes courage and defiance, while blue is the "intellectual" colour that suggests intelligence but also aloofness.Yellow is the "emotional" colour that boosts one's confidence and self-esteem, but it is also the colour of irrationality and anxiety. Green is a colour that the eye does not need to adjust to in any way and hence is the colour of balance and harmony, but also boredom and stagnation.And finally, there is the dimension of personal taste. People say everything, from your age, star sign, nationality and income group will affect the way that you appreciate colours and whether you like one shade over another.It is for all these reasons that choosing paint colours for the home is such a singular experience that sits exactly on the boundary between pai文件倉 and pleasure.The pain comes from the disagreements you will have with loved ones - heated arguments, even. Someone once told me that it was over a paint catalogue that she confirmed a nagging suspicion that she had married a man with irreversibly crass taste.There is also the pain of living with a mistake and knowing what a hassle it will be to undo it (even though you can).Here, everyone seems to have an embarrassing story about an awful colour he painted his room in his teenage years. Mine was bright pink, to go with black Ikea furniture, and another friend recently confessed to bright sea-blue walls with fish murals on them.But the pleasure (oh, the indescribable pleasure!) of going through 50 shades of grey, as I have been doing, and slowly ruminating on the dreams and desires that each one of them could unlock.Should the bedroom be swathed in a dense Chelsea Fog that befits the charming houses and buildings of the upscale London neighbourhood?Or should I go for something closer to the water - the greenish hue of a Seaside Village or the lights and shadows reflecting off a Silver Reef?Maybe it should be a whiter-grey like the vastness of a Snowfield, the softness of Swansdown or the purity of Song Porcelain.Perhaps it should be an abstract shade defined by a well-chosen and telling word - like Faithful or Dark Secret.In the end, lost in all the little colour squares barely distinguishable from one another, I found myself wondering if Maldivian Clouds really look any different from the clouds here or anywhere else in the world.Or if the Canadian Sky in Vancouver or Toronto is really as dreary as it looks to me here.It took me almost a week, in the end, to decide on all the new paint colours for the house.Instead of Zambezi Rocks, K.C. suggested a deeper, richer Kenyan Green for the backyard where the plants were, but my heart had long moved on, away from the African continent.I took the colour chart to breakfast.Sitting at Ya Kun one morning, I held the leaves of the potted plants next to me against one small colour sample square after another until I finally decided on Burmese Beige.A colleague who has long learnt to opt out of this game said she really didn't see the point of all this."Whatever colour you choose, you are going to be sick of it in a few months," she said matter-of-factly."So just paint everything white. You'll be much happier."I didn't dare tell her how many shades of white there were in the catalogue but I took the point.A life free of the daily regret of choosing Grey Squirrel over Silver Mink loomed tantalisingly before me.But it was only for a brief and fleeting moment before I took out my phone to type in the names and numbers that formed the colour codes of the fourth (and final) revision to the paint colours list that I would send K.C.; and hit "send".ignatius@sph.com.sg存倉

「全嘉大清掃，迷你倉尖沙咀歡喜辦喜事！」首次在在台舉辦的亞洲雙簧年會及嘉市第22屆國際管樂節，19日開幕，為歡迎國內外貴賓遊客，環保局長林建宏昨天在眷村「經國新城」升旗台前，帶領里長志工清掃誓師，全市84里總動員大掃除，整頓市容，百餘名清潔隊員同步清理環境，打造美麗家園迎賓。昨天上午西門街經國新城升旗台前舉辦清掃誓師活動，林建宏帶領喊口號「家家大清掃，環境一定mini storage，大家一條心，嘉園亮晶晶！」隨後大家一起動員，整理經國新城周遭環境綠帶、街道巷弄，清潔隊員陪同清理環境，打掃家園、整頓市容。「破壞市容菸蒂、檳榔渣、落葉最多！」里長志工動員整理綠帶、街道巷弄等環境，商家、超商、飯店員工也動起來，清掃認養區域，大家齊心協力，髒亂點很快清除乾淨。林建宏呼籲市民用誠摯心及美麗環境，接待參加音樂盛會貴賓，迎接即將到來的新年。迷你倉

來源 : 統計暨普查局根據統計暨普查局資料顯示，文件倉2012年有營運的批發及零售店舖有10,930間、街市攤檔及固定街檔共1,703間，按年分別減少32間及72間。2012年底的在職員工合計51,817人，按年增加7,266人。總收益達864.1億元（澳門元，下同），總支出為783.6億元，均按年上升28%。反映行業對經濟貢獻的增加值總額上升21%，為173.9億元；固定資本形成總額為17億元，增加104%。按行業分析，經營車輛及車用燃料銷售業店舖有900間，按年增加38間，在職員工有3,641人，增加744人。行業收益上升23%，達61.8億元；其中，豪華汽車需求增加，令機動車銷售收益上升30%，為39.7億元；車用燃料零售收益為13.5億元，增加11%。行業支出為58.4億元，上升20%；增加值總額有9.4億元，升幅達66%。固定資本形成總額為3,531萬元，按年減少30%。經營批發業店舖為4,033間，按年減少300間，在職員工共15,265人，增加739人。行業收益上升17%，為252.7億元；其中，糧食、飲品及煙草批存倉(79.5億元)和電器、藥物和衛生及清潔用品等消費品批發(64.6億元)分別佔總數31%及26%。行業支出增加15%，為241.3億元；增加值總額及固定資本形成總額分別為32.7億元及1.8億元，升幅分別為14%及9%。經營零售業店舖有5,997間，按年增加230間，在職員工共29,979人，增加5,833人。受惠於旅客購物消費持續增長及內部需求擴大，行業收益按年上升34%，達533.1億元；其中，鐘錶及金飾零售(162.9億元)和百貨零售(88.2億元)分別佔總數31%及17%。行業支出為470.1億元，上升37%，主要是購貨成本增加所致；增加值總額為128.7億元，增加21%。固定資本形成總額按年急升141%，達14.8億元，主因是購買商舖及大型裝修工程增加。2012年有營運的街市攤檔(757間)及固定街檔(946間)合共1,703間，按年減少72間；在職員工有2,932人，有薪酬員工只有448人。街市攤檔及固定街檔的收益(16.4億元)及支出(13.8億元)按年分別上升24%和26%；增加值總額為3.1億元，增加18%。儲存

即日-1/1/2014 百萬水晶聖誕 邀請本港首批原型師及情景模型創作大師黃偉麟，迷你倉以逾百萬顆的水晶珠打造 19 世紀維多利亞時代的聖誕大餐及家居布置，瑰麗絢燦，並於聖誕節期間，有聖誕老人及女郎於場內表演雜耍，大派聖誕糖果。 •地點：東涌東薈城•時間：雜耍表演 12月 21 至 22 日及 25 至 26 日 2pm-2:45pm / 4pm-4:45pm•查詢：2109 2933 20、21、23、24/12 冰上聖誕騷 聖誕商場表演特別多，又一城歡天雪地將舉行冰上舞動聖誕匯演，逾百位花式溜冰學員以傳統聖誕為主題，編排一系列優美而高難度的花式溜冰表演。另聖誕老人與聖誕女郎將於 12 月 22 至 25 日隨時於冰面出現，送上聖誕糖果和大家一起拍照留念。 •地點︰九龍塘又一城 UG 又一城歡天雪地•時間︰7pm•查詢︰2844 3588 即日-30/1/2014 不如，我�由頭�過何博欣以王家衛導演的《春光乍洩》內一句經典對白「不如，我�由頭�過」，重新演繹，讓平凡的都市人搖身一變，成為各自生活中的主角，如正在茶餐廳享受奶茶的老人家、早上赤裸上身躺在地上的地盤工人……•地點：柴灣嘉業街 18 號明報工業中心 A座 10 樓 Artify Gallery•時間：星期二至五 10am-7pm，星期六 10am-7pm，星期日及星期一休息•查詢：3543 1260 即日-2/1/2014 聖誕日玩夜探天際 100 只需購買一張正價門票，即可於日間及晚間各入場一次，體驗日夜不同的天際聖誕。日間有「飛越香港 3D 聖誕」及與聖誕老人合照；而夜間則可在維港上空一起尋找天際星座。而周末及公眾假期還會舉辦「天際聖誕玩藝坊」，與大家歡度佳節。 •地點：九龍站環球貿易廣場 100 樓天際 100 香港觀景台•時間：10am-9pm（最後進場 8pm）•門票：成人 $168，小童 / 長者$118，學生 $134 20/12-26/1/2014 我係小忌廉 POP-UP STORE Encore 當年是各大小朋友心目中的女神─小忌廉，再次訪港！POP-UP STORE 除多款日本空運到港精品，更有特別設計的香港限定小忌廉造型商品，值得收藏！店內還有以《我係小忌廉》為主題的彩虹攤位遊戲及夾公仔機，一眾 70 後朋友不容錯過！ •地點：銅鑼灣世貿中心 6 樓全層•時間：10am-11:45pm 即日-21/3/2014 Sony 大抽獎 贏 FIFA 世盃門票 凡購買指定 Sony 產品即可參加大抽獎，四回合抽獎共有 8 位幸運兒可贏取 2014 年 FIFA 世界盃決賽入場�兩張、雙人來回香港巴西里約熱內盧經濟客位機票及 4 晚雙人酒店住宿；顧客選購每件產品的價值愈高，獲抽獎機會就更多。（指定 Sony 產品請上網查詢）•查詢：2345 2966/ .sony.com.hk/fifa2014 19- 23/12 原塑 人說愛情魔力大，人為了愛可改變外觀與內在。美國編劇 Neil Labute 寫美麗碩士生改造平平無奇男子的愛情習作，殺傷力駭人。薛海暉、張學良及陳�沁組成方外無式的創團演出。 •地點：九龍城兆基創意書院•時間：12 月 19 至 21、23 日，7:30pm，12 月 21 日 2:30pm，12 月 22 日 12nn 及 4pm•門票：$200•查詢：9272 5207 即日-3-1/2014 SWAROVSKI 聖誕樹 閃亮機場 一棵近 15 米高的 Swarovski 聖誕樹現豎立在香港國際機場，它由接機大堂一直延伸至離港大堂，非常壯觀，樹身用上過百萬顆奧地利 Swarovski 水晶打造而成，設計時尚又富大都會節日氣氛。設互動拍照專區，與親友留下開心回憶！ •地點：香港國際機場 即日-23/12、2-20/1/2014 卡夫卡在布拉格 適逢卡夫卡誕生 130 周年，觀眾可透過圖片、文獻、小說與錄影了解這位在美麗城市布拉格出生，以德語創作的作家生平和作品。專門研究卡夫卡的李歐藩教授將於展覽最後一天晚上 7 時主持免費講座，門票先到先得。 •地點：灣仔香港歌德學院•費用：免費•查詢：2802 0088 即日-12/1 當代視覺藝術展 韓國藝術家李庸白的《破鏡》以液晶屏幕、雙向玻璃、碎裂聲效，讓觀眾自我對話，展現科技結合藝術的力量。香港藝術中心第五屆旗艦視藝展，廣邀包括他在內的亞洲藝術家探索科技啟發藝術。 •地點：灣仔香港藝術中心•費用：免費•查詢：2582 0200 18-22/12 投選！最想睇旅遊計劃 看《三個小生去旅行》，四哥去邊我們無得選，頂多覺得佢帶《U Magazine》旅遊天書有品味，今次就唔同喇！M21 舉辦的「非常旅人任務」，首季以「保衛地球」為題，公開徵集同環保或地球保育有關的旅遊計劃，獲選的項目最高可獲港幣 $80,000 元資助，幫人圓夢之餘，尚有 M21 隨團攝製隊將旅程拍成紀錄，同觀眾分享。最重要，是可以一人一票，投選你最想睇的旅遊計劃。 非常旅人任務 13-22/12 新界無戰事 滿道編劇，張秉權執導，五位演員分飾二十多個角色，加入南音與客家山歌，回到十九世紀末新界北區鄉民對抗英軍捍衛家園的不為人知歷史一頁。致群劇社、香港戲劇工程辦合製作。 •地點：上水山區大會堂•時間：12 月 13 日、19 日 4pm 12 月 14、15 及 21 日 3pm、8pm，12 月 22 日 3pm•門票：$120•查詢：amitydrama2009@yahoo.com.hk 即日-1/1/2014 聖誕獻良機大抽獎 使用電子貨幣於 6 大商場內指定商舖即日單一消費滿 $100 或以上，即可換領「聖誕獻良機大抽獎」抽獎券一張；即日單一消費滿 $200 或以上則可換領 2 張；如此類推，每次即日單一消費最多可換領抽獎券 10 張。有機會贏取 Samsung Note 3 一部。得獎名額10名。 •地點：杏花新城東翼一樓推廣活動攤位 、綠楊坊二樓推廣活動攤位、連理街推廣活動攤位、Citylink 推廣活動攤位、海趣坊推廣活動攤位、駿景廣場顧客服務中心 •換領抽獎券日期：逢星期六、日及公眾假期 12nn-10pm text︱Helen、Ami edit︱Helen art︱K 即日-29/12 藝緣畫會 活化牛棚 展示 17 位藝術家作品包括繪畫、數碼電腦版畫、雕塑、裝置藝術等，更設「每人都是小畫家」工作坊，參加者可透過電腦中的小畫家創作數碼版畫，即時打印，與創會會長陳餘生作品並列展出，組成大型拼貼圖。•地點：馬頭角道 63 號牛棚藝術村 12 號單位；牛棚藝術村 8 號單位 (工作坊) 21-25/12 高蹺王巡遊表演 香港鮮有欣賞到踩高蹺表演，9 位參加了首屆「香港高蹺王」比賽而進入決賽的參加者，將於聖誕期間，在香港多處打自存倉成家傳戶曉的角色為主題造型，進行巡遊表演拉票，而大家更可以於 facebook 投票，選出首屆「高蹺王」！•地點：尖東百週年紀念花園、尖沙咀中心及帝國中心•時間：7:30pm-9:30pm，網上投票 即日至 1 月 1 日•查詢：2369 6662 tsimshatsuicentre 即日-5/1/2014 推出聖誕戲偶劇場 香港迪士尼樂園的「反斗奇兵大本營」、「灰熊山谷」及「迷離莊園」現每日上演溫馨小故事：如「反斗玩偶劇場」就設互動環節，大家可以參與演繹當中角色；而「灰熊手偶劇場」就訴說熊寶寶的冬日心願；還有「亨利爵士皮影劇場」的奇異故事，令大家樂在其中。 hongkongdisneyland 12-15、18-20 及 26/12 奇幻魅影魔術表演 又一城除了有充滿�芬蘭聖誕氣氛的聖老人村落，周末期間更有一連串精采表演；其中有由澳洲國際魔術大師 John Taylor 呈獻的「奇幻魅影魔術表演」，他的拿手絕活將一一呈現大家眼前，萬勿錯過！ •地點：又一城經典聖誕舞台 LG2 層•時間：12 月 14、15、及 20 至 26 日 5pm-6pm，12 月 12、13、18 及 19 日 7pm-8pm•查詢：2844 2223 14/12-1/1/2014 樂天小熊 現身昂坪市集 超過 100 款可愛造型的樂天小熊，現遍布東涌纜車站及昂坪市集每個角落，市集內更有多個以樂天小熊為主題的布置場景，等大家影相留念；還有一個 6 呎高的樂天小熊將不定時出沒，向大家大派朱古力小熊餅。•地點：東涌纜車站及昂坪市集•查詢：3666 0606 np360hk 20/1 截止報名 無國界醫生野外定向 想親身體驗無國界醫生救援人員的艱辛和災區的種種限制，並更認識他們的工作，可參加無國界醫生野外定向，今次大會更將醫療設施和場景搬入賽事中心，參加者有機會看到前�手術室治療病人的緊急情況，並一嘗營養治療食品。•舉行日期：2014 年 3 月 9 日•地點：長洲•出發時間：9am 起•報名及查詢：.msf.hk/oc 或 2959 4249•備註：除設「精英組」及「公開組」外，亦有「體驗組」和「親子組」。 即日-29/12 賀聖誕禮品巡禮 有多款聖誕精品、布置飾品、派對禮品、時尚服飾、電子產品等，只需於店內購物滿 $300（折扣後）及出示上載於「香港．設計廊」Facebook專頁的優惠券，即送 O+ 胡椒鹽罌一個，數量有限，送完即止。•地點：灣仔港灣道1號香港會議展覽中心地下「香港．設計廊」•時間：10am-8:30pm•查詢：2584 4146 HKTDC.DesignGallery 12-15/12、19-22/12 細味•禮品薈 有多位本地設計師及社福機構在科學園內的 30 個攤位售賣創意精品及手工藝品；更設免費親子工作坊，導賞團「科學探索行」、彈彈床、扭氣球等，加埋園內中西餐廳提供的美食，滿足晒小朋友食、買、玩大個願望！•地點：科學園第二期浚湖樓地下•時間：11:30am-6pm•費用：免費•查詢：.hkstp.org / 2629 6837 即日-29/12 禮物轉贈大行動 聖誕節是送禮及收禮的時候，但亦為每年造成了很多「禮餘」問題，不想浪費送贈者的心意，就將家中的積存及今年所收的剩餘禮物捐出，轉贈予有需要家庭，及於救世軍旗下 16 間家品店重新上架。•收集地點：將軍澳東港城一樓回收箱－顧客服務中心旁（港鐵坑口站 A1 出口）•時間：10am-10pm•募集四大「禮餘」：現金禮券、禦寒衣物、小型家電、益智玩具及書籍•查詢：2628 7399 即日-1/1/2014 「蠟筆小新」回顧展 商場除化身為「蠟筆小新鬼馬學園」，學園內還設「蠟筆小新」回顧展覽室，公開展出已故《蠟筆小新》作家臼井儀人之珍貴手稿，讓大家一睹《蠟筆小新》的誕生過程；還可欣賞到少爺占為小新及小白重新設計的服飾。•地點：愉景新城discoveryparkshoppingcentre 即日-1/1/2014 輕鬆小熊遊樂園 打造「輕鬆小熊 10 週年之星光遊樂園」，設夢幻迴旋木馬、香甜班戟派對及小熊演奏樂團場景布置，還有日本空運到港的巨型吹氣輕鬆小熊與大家揮揮手；輕鬆小熊更與 Korilakkuma小白熊舉行限定見面會，與 Fans 們見面擁抱。•地點：尖沙咀 The ONE UG 2 中庭•時間：10am-11pm，限定見面會 12 月 15、22、25 及 26 日 3pm 及 4pm•備註：見面會入場券將在活動舉行當日下午 1pm 免費派發，憑券入場可與兩小熊合照 1 張•查詢：3106 3640 即日-31/12 MegaBox 6 小時泊車優惠 於推廣期逢星一至四 5pm 後入閘及單一消費滿 $200 或以上即可享用 4 小時免費泊車服務，單一消費滿 $300 或以上即可享用 6 小時免費泊車服務。 •換領地點：九龍灣 MegaBox G 及 L9 顧客服務中心•時間：5pm-10:30pm（星期五、六、日及公眾假期除外）•查詢：2989 3000 14/12-2/2/2014 全城尋寶 贏比利時之旅 需到指定店舖與穿上由本地時裝設計系學生設計的特色服裝之「撒尿童子」銅像及一件比利時設計或產品合照，再「讚好」（Like）Facebook 專頁，並將照片上載至 Facebook 專頁。獲最多「讚好」的 8 張參賽照片，有關參加者將可競逐豐富獎品，包括比利時產品及三天比利時之旅。•參與店舖資料請上網查詢：.belgianspirit.be/ mannekenpishk reminder 20/12 暗中享用聖誕大餐 帶領大家體會不一樣的聖誕，推出「深『黑』聖誕 」奇妙之旅，參加者可體驗有多樣歐陸聖誕元素及創新感官效果，之後還可在晚宴廳摸黑品嘗有三道精美菜式的聖誕大餐，更有「暗」中表演、幸運大抽獎及交換禮物環節，雖然「看不見」卻令你暖在心窩。 dialogue-in-the-dark •地點：美孚景荔徑 8 號盈暉家居城 2 樓 215 室黑暗中對話體驗館•時間：聖誕大餐 6:15pm-9:30pm，•費用：$1,000 已包深『黑』聖誕之旅費用 （ 45 分鐘）•語言：雙語（廣東話及英語）•查詢：2891 0438 Start 即日起 Hello Kitty 八達通配飾形象百變的 Hello Kitty 永遠都係咁受歡迎，皆因無論男女老幼都係佢 Fans！八達通推出全新「Hello Kitty 八達通配飾」，有彩蝴蝶結及搖滾星星造型，成年版就附有銀鏈以作掛飾，而小童版就有頸繩，方便使用。 octopus hk •售賣地點：全� 7-Eleven 便利店及八達通網上商店•費用：每款 $178，不設按金及儲值額。•查詢：2266 2222 text、edit︱c art︱Keith 迷你倉

為增加企業競爭力，儲存財政部南區國稅局昨（13）日表示，企業招待經銷商及客戶的旅遊費用，因具獎勵性質，可由交際費改列為其他費用，並可按實際支出金額列帳，不受費用限額的申報限制。又到歲末年終，公司行號即將整理今年的帳證，南區國稅局昨天發出新聞稿，特別提醒公司行號注意今年度修正的課稅新規定。為協助企業拚經濟，財政部稍早已發佈解釋令，自今（102）年起，企業提供達一定業績標準的經銷商或客戶，具有獎勵性質的支出或佣金，准予列為企業的其他費用，並依所得稅法規定，列單申報主管稽徵機關，及填發免扣繳憑單給經銷商及客戶。過去企業招待經銷商或與業務有關的客戶出國旅遊，必須以交際費項目申報，且有金額上限；依據規定，一般企業的交迷你倉費，全年進貨額在3千萬以下者，須以全年進貨價的千分之1.5為限。為使課稅合理化，財政部也重新定義企業「交際費」的範圍，企業在營利活動過程中，為塑造或改進獲利環境、建立良好公共關係所支出的費用，即可認定為交際費。官員進一步解釋，交際費具有「任意支付」，以期待增加未來交易的目的，通常與營業收入之間，並無必然的因果關係。財政部表示，自今年起，企業如事先與經銷商或客戶約定，以達到一定購銷數量或金額，作為招待旅遊之條件者，可改列其他費用，以真實反映企業的經營利潤。不過，會計師提醒，財政部雖放寬獎勵旅遊的支出，可按實際支出金額列帳，但在實務上，稅捐機關常要求企業必須出具有受招待者簽名的單據，否則容易被國稅局剔除補稅。儲存倉

/NOT FOR DISTRIBUTION TO U.迷你倉S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW./TORONTO, Dec. 13, 2013 /CNW/ - Mercari Acquisition Corp. ("Mercari" NEX: MV.H) is pleased to announce that it, together with its wholly-owned subsidiary Mercari Subco Inc. ("Mercari Subco"), has entered into a definitive agreement dated December 13, 2013 (the "Amalgamation Agreement") pursuant to which Mercari Subco will amalgamate (the "Amalgamation") with Concordia Healthcare Inc. ("Concordia") to complete an arm's length qualifying transaction (the "Transaction") in accordance with the policies of the TSX Venture Exchange (the "TSXV"). The Amalgamation is structured as a three-cornered amalgamation and as a result the amalgamated corporation ("Amalco") will become a wholly-owned subsidiary of Mercari at the time of the completion of the Amalgamation. The Amalgamation Agreement will be made available on SEDAR at .sedar.com. Mercari has received conditional approval from the Toronto Stock Exchange (the "TSX") to have the common shares of the Resulting Issuer (as defined below) listed for trading on the TSX following the Transaction. Mercari anticipates closing the Transaction on or about December 20, 2013.About ConcordiaConcordia is an integrated healthcare company incorporated under the Business Corporations Act (Ontario) (the "OBCA") that targets three areas: (a) legacy pharmaceutical products; (b) specialized healthcare distribution that services the growing diabetic market; and (c) the acquisition and/or development of orphan drugs. These three business units are run as separate divisions but are inter-related. The cash-flow from legacy pharmaceuticals is used to fund operations and is also intended to fund the expansion of indications for potential orphan drugs. The specialized healthcare distribution division provides additional growth and cash-flow generation. Additionally, through its registered pharmacy operation this business is intended to provide a specialty distribution capability for orphan drugs once acquired and/or developed. All three of these divisions are operated through a corporate organization that provides executive leadership, industry experience, financial and capital markets experience, and an efficient tax structure. Concordia operates out of facilities in Oakville, Ontario, Kansas City, Missouri and Bridgetown, Barbados.Concordia's legacy pharmaceutical business was acquired in May 2013. Concordia's legacy pharmaceutical business includes the management and acquisition of legacy pharmaceutical products, both with patent life and exclusivity remaining (pre-legacy) and products that have reached full maturity but continue on a predictable revenue generation path, collectively referred to as legacy products.Concordia's existing portfolio of legacy drugs (the "Existing Portfolio") consists of Kapvay (clonidine extended release tablets), Ulesfia (benzyl alcohol) Lotion 5% and Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets).Concordia's specialized healthcare division (the "SHD Division") was acquired in October, 2013, with an effective date of August 1, 2013. The SHD Division is a United States national Internet and mail-order provider of diabetes testing supplies, pharmaceuticals, diabetic shoes, orthotic braces and other home medical equipment. The SHD Division operates primarily out of office and warehouse facilities located near Kansas City, Kansas.Concordia's orphan drugs division is intended to provide growth opportunities through the expansion into new indications for existing legacy products or the acquisition of approved orphan drugs and further expansion within their identified markets. In the initial execution of its orphan drug strategy Concordia, through its subsidiaries, entered into an agreement and plan of merger (the "Pinnacle Purchase Agreement") on November 8, 2013 to acquire Pinnacle Biologics, Inc. ("Pinnacle"). The legacy pharmaceutical product owned by Pinnacle has three oncology indications approved by the FDA and is being developed for the treatment of an additional rare form of cancer. Closing of the Pinnacle Purchase Agreement is not a pre-condition to completing the Amalgamation.Summary of Financial Information for ConcordiaThe following table sets forth selected consolidated financial information for Concordia as of and from the date of incorporation on December 5, 2012 to the period ended September 30, 2013. Concordia's first transaction was consummated on May 6, 2013. This information is derived from audited consolidated financial statements for the period ended September 30, 2013 prepared in accordance with International Financial Reporting Standards. All of the following information is reported in US dollars.US$For the period ended September 30, 2013Revenue $23,763,479Net Income 9,499,287Basic earnings per share 2.08Diluted earnings per share 1.63Total Assets 79,370,498Total Liabilities 59,727,063Proposed Concordia FinancingBefore the effective time of the Amalgamation, Concordia proposes to complete a private placement (the "Private Placement") of subscription receipts (the "Subscription Receipts"). Pursuant to the Private Placement, Concordia will offer up to CDN$30,000,000 of Subscription Receipts at a price of $6.25 per Subscription Receipt. Each Subscription Receipt will be exchangeable for one common share of Concordia. Pursuant to the terms of the Amalgamation Agreement, holders of Concordia common shares exchanged for the Subscription Receipts will receive common shares of Mercari upon completion of the Amalgamation (the "Resulting Issuer") on the basis of one Resulting Issuer common share for each Concordia common share held. The completion of the Private Placement is not a condition to closing the Transaction. In addition, Concordia has granted an option to the agents of the Private Placement (the "Agents") to purchase up to an additional 15% of the number of Subscription Receipts sold under the Private Placement on the same terms as under the Private Placement.The Agents will be entitled to receive a cash commission equal to 6% of the gross proceeds from the Private Placement (the "Agents' Commission") together with options (the "Agents' Compensation Options") entitling the Agents to subscribe for that number of common shares of Concordia as is equal to 4.0% of the total number of Concordia common shares issued pursuant to the exercise of Subscription Receipts under the Private Placement. Each Agents' Compensation Option will be exercisable to purchase one Concordia common share at the price of CDN$6.25 per common share for a period of 24 months from the date that the proceeds of the Private Placement are released from escrow in accordance with the terms of the Private Placement. The Agents' Compensation Options will be exchanged for Resulting Issuer Options, pursuant to the Amalgamation Agreement.It is anticipated that the net proceeds from the Private Placement will be used as follows:Gross proceeds from the Private Placement $30 millionAgents' Commission $1.8 millionTo be applied to Pinnacle acquisition $28.2 millionNotwithstanding the foregoing, management of Concordia and the Resulting Issuer may determine that it is in the best interests of Concordia or the Resulting Issuer to allocate the net proceeds of the Private Placement in a manner that is different than the foregoing and the net proceeds may be allocated accordingly. There may be circumstances, where for sound business reasons, the reallocation of funds may be necessary in order for the Resulting Issuer to achieve its stated business objectives.About the TransactionMercari will hold a special meeting of its shareholders on December 16, 2013 to approve, among other things, (i) a change in the name of Mercari from "Mercari Acquisition Corp." to "Concordia Healthcare Corp." or such other name as is agreed to by Concordia and Mercari; (ii) the appointment of the proposed directors for the Resulting Issuer; (iii) approval of a stock option plan for the Resulting Issuer; (iv) a consolidation of the common shares of Mercari on the basis of one (1) post-consolidation Mercari common share for every 48.08 pre-consolidation common shares of Mercari; and (v) and a change in Mercari's registered office address to the registered office address of Concordia. Details regarding the special meeting of the shareholders of Mercari are available in a management information circular dated November 11, 2013 that has been provided to shareholders of Mercari. In addition, the Amalgamation will be approved by the shareholders of Concordia by way of consent resolution prior to the Amalgamation.Pursuant to the terms of the warrant certificates representing the Concordia common share purchase warrants (the "Concordia Warrants"), the holders thereof may exercise the Concordia Warrants by delivering to Concordia prior to the date of the Amalgamation, a completed exercise form and payment of the aggregate sum of $1.00. It is intended that all of the issued and outstanding Concordia Warrants will be exercised in such manner prior to the Amalgamation.Under the terms of the Amalgamation Agreement, at the effective time of the Amalgamation, among other things:(a) each holder of Concordia common shares (except for Concordia common shares held by holders that have validly exercised their dissent rights in connection with the special resolution approving the Amalgamation) shall exchange their Concordia common shares for common shares of the Resulting Issuer instead of common shares of Amalco, on the basis of one (1) fully paid and non-assessable Resulting Issuer common share for every one (1) Concordia common share held; and(b) subject to receipt of all required regulatory approvals, each holder of options issued under Concordia's stock option plan (each a "Concordia Option") or Agents' Compensation Options outstanding immediately before the effective date of the Amalgamation shall exchange each such Concordia Option or Agents' Compensation Option, as the case may be, for one (1) option issued under the Resulting Issuer's stock option plan (each a "Resulting Issuer Option") with such Resulting Issuer Option having the same terms as the Concordia Option or Agent's Compensation Option, as the case may be, being exchanged, and each such Concordia Option or Agents' Compensation Option shall be cancelled. The exercise price for each Resulting Issuer common share underlying the Resulting Issuer Option will be equal to the exercise price per Concordia common share under the Concordia Option or the Agents' Compensation Option, as the case may be, in effect immediately prior to the Amalgamation on a post-consolidation basis.The completion of the Amalgamation is conditional on obtaining all necessary regulatory and shareholder approvals in connection with the matters described above and other conditions customary for a transaction of this type.Immediately after the completion of the Transaction, on a non-diluted basis and after giving effect to the Mercari consolidation, the shareholders of Mercari will own approximately 276,622 common shares of the Resulting Issuer and the shareholders of Concordia will own approximately 16,763,051 common shares of the Resulting Issuer (assuming 5,520,000 Subscription Receipts are issued pursuant to the Private Placement).Terei International Limited, a corporation incorporated under the laws of Hong Kong, will, after giving effect to the Transaction, beneficially own, control or direct, directly or indirectly, approximately 3,072,500 common shares of the Resulting Issuer, representing approximately 14.37% of the issued and outstanding common shares of the Resulting Issuer on a fully diluted basis. Mark Thompson, a resident of Toronto, Ontario, will, after giving effect to the Transaction, beneficially own, control or direct, directly or indirectly, approximately 2,398,750 common shares of the Resulting Issuer, representing approximately 11.22% of the issued and outstanding common shares of the Resulting Issuer on a fully diluted basis.Arm's Length TransactionThe Transaction is an arm's length transaction in accordance with the policies of the TSXV and is not subject to Mercari shar自存倉holder approval.Proposed Management and Board of Directors of the Resulting IssuerUpon completion of the Transaction, it is anticipated that the persons identified below will serve as directors and officers of the Resulting Issuer.Mark Thompson - Chief Executive Officer, President, DirectorMr. Thompson is the founder, CEO, President and a director of Concordia. He previously served as the former Senior Vice President and General Counsel of Legacy Pharma Limited Partnership and was a co-founder of Trimel Pharmaceuticals and Tribute Pharmaceuticals Inc. From 2002 to 2005, Mr. Thompson was employed by Biovail Corporation (currently Valeant), where he held the title of Vice-President, Business Development and, before that, Associate General Counsel. While at Biovail Corporation, Mr. Thompson was actively involved in mergers and acquisitions transactions valued at over $2 billion. Prior to joining Biovail Corporation, Mark was an associate at Osler, Hoskin and Harcourt LLP. Mark holds an H.BA, and MA from York University and an LL.B from the University of Ottawa.Leith Tessy - Chief Financial Officer, Secretary-TreasurerMr. Tessy has 25 years of international experience as a finance and operations executive. He has been successful driving mergers and acquisitions transactions (with total transaction value exceeding $1 billion), integrating acquired companies and expanding operating margins. Previous roles held include: CFO then COO of LG Nortel, a JV between Nortel Networks and LG Electronics based in Seoul, South Korea (under Mr. Tessy 's leadership, the company grew from approximately $500 million to approximately $1 billion, delivering 30% EBITDA margin), CFO of Nortel Networks' Global Carrier Networks group (at approximately $5 billion revenue, Nortel's largest, most profitable division), and SVP Finance at Nuance Communications (a highly acquisitive software company). Mr. Tessy holds an Industrial Engineering degree from University of Toronto and an MBA from Ivey School of Business, University of Western Ontario.John McCleery - Managing Director, Chief Financial Officer (of Concordia Pharmaceuticals Inc. and Concordia Laboratories Inc.)Mr. McCleery is the Managing Director and CFO of Concordia Pharmaceuticals Inc. and Concordia Laboratories Inc., which are subsidiaries of Concordia. He has 30 years of international experience as a senior financial and operational executive. He developed and managed the Enterprise Risk Management and Compliance program for Valeant Pharmaceuticals International Inc. (formerly Biovail Corporation), reporting company risks to the board of directors. Mr. McCleery chaired the Compliance Committee and the Canadian Investment (RSP; DPSP) Committee. Mr. McCleery served as Vice President and General Manager of Valeant Laboratories (Barbados) SRL (formerly Biovail Laboratories International SRL) the principal operating subsidiary where he had responsibility for managing intellectual property, treasury activities, research and development programs and business partner relationships with Merck, Johnson and Johnson, Wyeth, Forest and Teva etc. He was also a Director and Vice President, Treasurer of Valeant Insurance Incorporated (formerly Biovail Insurance Incorporated). Mr. McCleery served as Vice President, General Manager and Chief Financial Officer of Trimel BioPharma SRL and was responsible for all operational and financial management of the principal operating subsidiary of Trimel Pharmaceuticals Corporation. John is a Chartered Professional Accountant (CPA) and a Chartered Accountant (CA) having earned his designations with the Toronto office of PricewaterhouseCoopers.John Huss - DirectorAfter 20 years in the pharmaceutical and biotechnology industry, Mr. Huss founded H&P Labs Inc., a biotechnology company focused on early stages of drug development (Phase I & II) in humans. Before that Mr. Huss was President and CEO of Theratechnologies in Montreal. Since his return to Canada in 2010, he sits on the Board of BioQuebec and since 2012 he also serves on its Executive Committee, as Vice-President. Mr. Huss worked for sanofi from 1999 to 2010 in Germany, Canada, Switzerland and France. He joined sanofi in 1999 as a Business Unit Director for the German affiliate. In 2001, Mr. Huss joined the Canadian affiliate as Vice-President, Sales and Marketing in Toronto and moved to Montreal after the acquisition of Aventis. He became General Manager of the Swiss affiliate of sanofi-aventis in January 2007, based in Geneva. In August 2009, Mr. Huss joined the Head Office in Paris and worked next to the Chief Executive Officer, Chris Viehbacher, as Chief of Staff. Mr. Huss joined the pharmaceutical industry in 1990 and for 6 years performed various Sales and Marketing functions for Merck & Co. in the United States, Germany and Switzerland. In 1996, he was offered a position with F. Hoffman-La Roche as an Internal Product Manager at their Basel headquarters.Ron Schmeichel - Director, Non-Executive Chairman of the Board of DirectorsMr. Schmeichel has 18 years of experience in high-yield credit, leveraged loans, buy-outs and equity capital markets in Canada and the US. For the past 3 years, he has served as the President and CEO of Windsor Private Capital, a firm that manages both credit and private equity capital funds. The firm specializes in providing credit and equity lines for management buy-outs, recapitalizations, bridge and mezzanine loans and minority equity ownership to small/mid market United States and Canadian companies. Prior to this, Mr. Schmeichel was one of the founders and partners of JJR Capital Corp., a Toronto based merchant banking firm that specialized in reverse merger transactions on the TSXV. Since Concordia's inception, Mr. Schmeichel has served as the non-executive Chairman of the Concordia board of directors as well as a mergers and acquisitions advisor on six pharmaceutical/healthcare transactions, including the two foundational acquisitions that make up Concordia currently. Mr. Schmeichel has been on the board of over 15 venture-listed public companies and has served as a director and audit committee chair of one TSX-listed company. For the past 12 years, Mr. Schmeichel has been a guest lecturer at the University of Western Ontario, Faculty of Law, as well as the Ivey School of Business. He currently serves as a member of the Ontario Local Area Committee to the Toronto Stock Exchange-Venture Group. Mr. Schmeichel received a BA degree, with Merit, from York University in 1992 and a Juris Doctorate degree from the University of Western Ontario in 1995.Doug Deeth - DirectorMr. Deeth is a partner with the law firm of Deeth, Williams & Wall LLP. He is the former President of the Intellectual Property Law section of the Canadian Bar Association and has 25 years of experience in the pharmaceutical industry.Jordan Kupinsky - DirectorSince 2008, Mr. Kupinsky has been a Managing Director with Windsor Private Capital Inc. and its predecessor JJR Capital Corp. Prior to joining Windsor, he was a Vice President at Greenhill & Co., an independent global investment banking firm, listed on the NYSE, focused on mergers & acquisitions and financial restructuring from March 2006 to May 2008. Prior to joining Greenhill, Mr. Kupinsky held the positions of Vice President of Corporate Development and General Counsel at Minacs Worldwide Inc., a publicly traded company on the TSX from July 2002 to February 2005. Mr. Kupinsky began his career practicing corporate and securities law at Torys LLP in Toronto (from 1997 to 1999) and was also an investment banking associate at Houlihan Lokey Howard & Zukin from 1999 to 2002. He holds a joint MBA and JD degree from the Schulich School of Business and Osgoode Hall Law School at York University. Mr. Kupinsky is currently a director of Atlas Financial Holdings Inc. where he chairs the audit committee. Mr. Kupinsky has served as a director of companies on the TSX and on the TSXV, including having served as a director of Xceed Mortgage Corporation from May 2012 through July 2013 when the sale of Xceed to MCAN Mortgage Corporation was completed.Filing StatementIn connection with the Transaction and pursuant to TSXV requirements, Mercari has filed a filing statement dated December 13, 2013 (the "Filing Statement") on SEDAR (.sedar.com). The Filing Statement contains details regarding the Transaction, the Amalgamation, the Private Placement, Mercari, Concordia and the Resulting Issuer.SponsorConcordia has engaged GMP Securities L.P. and Canaccord Genuity Corp. (together, the "Sponsors") as its sponsors in connection with the listing of the common shares of the Resulting Issuer on the TSX.Completion of the Transaction is subject to a number of conditions including, but not limited to, TSXV acceptance and, if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all.Investors are cautioned that, except as disclosed in the filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in securities of a capital pool company should be considered highly speculative.The TSXV has in no way passed upon the merits of the Transaction and has neither approved nor disapproved the content of this press release.The Sponsors, subject to completion of satisfactory due diligence, have agreed to act as sponsors in connection with the listing of the common shares of the Resulting Issuer on the TSX. An agreement to sponsor should not be construed as any assurance with respect to the merits of the transaction or the likelihood of completion.* * *This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction.ANY SECURITIES REFERRED TO HEREIN WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 (THE "1933 ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO A U.S. PERSON IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE 1933 ACT.Notice regarding forward-looking statements:This release includes forward-looking statements regarding Mercari, Concordia, and their respective businesses, which may include, but is not limited to, statements with respect to the completion of the Transaction, the Private Placement and the acquisition of Pinnacle, the terms on which the Transaction, Private Placement and acquisition of Pinnacle are intended to be completed, the use of the net proceeds from the Private Placement, the ability to obtain regulatory and shareholder approvals and other factors. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, including completion of the Transaction, the Private Placement and the acquisition of Pinnacle, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the pharmaceutical industry, failure to obtain regulatory or shareholder approvals, economic factors, the equity markets generally and risks associated with growth and competition. Although Mercari and Concordia have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Mercari and Concordia undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.Mercari Acquisition Corp.CONTACT: Elena Masters, Director of Mercari Acquisition Corp. at 416 972 9993.迷你倉

明年LED照明滲透率上看20％，mini storageLED近期成為市場當紅炸子雞。身兼億光（2393）董事長、晶電（2448）副董事長的葉寅夫昨（13）日指出，LED市場成長看好，以上游的晶片廠而言，晶電受惠程度高於大陸業者。而有下游業者評估，從明年國際前三大照明廠競相推出新品，承接歐美OEM訂單的台廠將得利。 業界預期，明年LED照明滲透率將達20％，後年甚至有機會上看30％。葉寅夫指出，就LED晶片鏈來看，大陸一線廠向台灣產業借將，使大陸一線廠技術與台灣差距已經不大，但是晶電還是享有較高的品牌知名度，他認為晶電受惠程度將高於大陸廠。葉寅夫指出，明年封裝廠除了衝量之外，成本控制也相當重要，掌握成本與通路是明年的關鍵。億光旗下100％子公司億光固態照明今年台灣區營收達10億元，明年預計跳升至20億元，出貨量則可望大增1.5倍，該公司資本額為4億元，是少迷你倉橫跨商用照明、特殊照明、工程標案的照明廠。由於布建通路相當燒錢，不過從明年開始，億光固態照明在台灣就有機會進入獲利階段。 另有下游業者指出，明年LED照明滲透率爬升時，國際前三大照明廠歐司朗、飛利浦和GE一定會推出低價的照明產品，台灣承接歐美OEM相關訂單的廠商會先獲利。 業者強調，台系品牌明年則處於衝量階段，且必須先經過一段犧牲利潤的陣痛期，把量刺激出來，因此明年受惠程度會落後OEM廠。業者也坦言，明年照明滲透率雖有機會大幅提升，但是消化晶片產能的主力還是背光源，以目前背光源滲透率高達95％來看，晶片產能閒置的情況會有所改善，但恐怕還是呈現供過於求狀態。 LED族群今年以來沉澱已久，挾其籌碼乾淨、低價、低本益比優勢，類股強勢表態，昨日龍頭股億光觸及漲停，創下波段新高價63.2元，中低價位的東貝、佰鴻、泰谷、湯石、光鋐盤中均見漲停。文件倉

迷你倉 本報訊筆者從中國鐵路總公司瞭解到，鐵路部門的官方手機購票客戶端———“鐵路12306”12月8日上線試運行，向廣大旅客提供列車信息查詢、購票等服務。“鐵路12306”應用圖標為藍白底色，上方為紅色的中國鐵路路徽，路徽下方標有“中國鐵路”字樣。“鐵路12306”免費供旅客下載使用。使用安卓系統的手機用戶可直接從.1 2306.cn網站下載，使用蘋果手機的用戶可從蘋果應用商店“APPSTORE”下載。試運行期間，如遇到購票不暢等問題，請廣大旅客諒解，並及時選擇其它方式購票，以免耽誤您的行程。(孫雅彬)自存倉